Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0032285 (pneumonia)
 54,520 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The importance of Mycoplasma pneumoniae as a pathogen of human infectious diseases, particularly of respiratory infections, has been well recognized. However, the details of the mechanism through which lung tissue damages are produced in mycoplasmal infection has not been fully understood. It has been pointed out that beside the direct invasive process certain immunological responses to the deposited microbes are crucial in development of mycoplasmal pneumonia. In the present study, we aimed at elucidating the role of neutrophils in producing pneumonia due to Mycoplasma pneumoniae in hamsters. For this purpose, hamsters were divided into two groups; the one not pretreated and infected with Mycoplasma pneumoniae and the other immunosuppressed by 60Co irradiation and infected. A serial determination of the numbers of mycoplasmal cells recovered from the treacheal tissue and bronchoalveolar lavage fluid (BALF) and analysis of cellular components in BALFs were carried out. The severity and the nature of pathological changes produced in the lungs were evaluated and scored on the basis of microscopic findings. As a result, it was found that the numbers of mycoplasmal cells recovered from both tracheal tissues and BALFs reached maximum on the seventh day of infection in both groups and decreased rapidly. There no apparent difference was found between the two groups in number of cells recovered. In the not-irradiated control groups, the percentage of polymorphonuclear leukocytes (PMNs) in BALF was very high on the seventh day and then they were replaced by lymphocytes by the 21st day of infection.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:[Role of transiently accumulated neutrophils in the lung of hamster in development of pneumonia due to Mycoplasma pneumoniae]. 207 56

A total of 207 cases were selected to evaluate the diagnostic value of C-reactive protein (CRP) in pulmonary infections. The mean +/- SD of CRP values in various pulmonary infections were as follows: 18.62 +/- 11.34 micrograms/ml for 32 cases of exudative-fibrotic tuberculosis; 15.98 +/- 16.66 micrograms/ml for 15 cases of tuberculous pneumonia; 25.61 +/- 18.96 micrograms/ml for 29 cases of tuberculous effusion; 16.66 +/- 10.18 micrograms/ml for 11 cases of tuberculous cavity; 81.1 +/- 24.9 micrograms/ml for 10 cases of miliary tuberculosis; 36.4 +/- 22.1 micrograms/ml for 19 cases of mycoplasmal pneumonia; 241 +/- 72 micrograms/ml for 38 cases of bacterial pneumonia; 225 +/- 65 micrograms/ml for 30 cases of bacterial pneumonia with effusion; 169 +/- 50 micrograms/ml for 16 cases of lung abscess. The CRP values of other pulmonary infections were as follows: 20.6, 20.8 micrograms/ml for two cases of Strongyloides stercoralis pneumonia; 7.4, 1.6 micrograms/ml for two cases of aspergilloma; 11.2, 12.4, 7.6 micrograms/ml for three cases of Pneumocystis carinii pneumonia. Serial changes in CRP values in 13 cases of well-treated bacterial pneumonia showed that values of CRP decreased to below half of the initial value on the 3rd to 4th day, and returned to about normal value on the 10th to 13th day. The study suggested that: a) various types of infections had different levels of CRP values, b) level of CRP values was determined both by the pathogen and the severity of inflammation, c) serial CRP values in bacterial infection could be used as a guide in treatment.
 ...
PMID:Quantitative C-reactive protein in pulmonary infections. 221 64

We studied the clinical efficacy of ofloxacin (OFLX) in the treatment of 13 cases of Mycoplasma pneumoniae pneumonia. OFLX was given to each patient orally at 200 mg/dose, 3 doses daily. One case was excluded because of a side effect i.e., nausea. In 12 evaluable cases, the clinical efficacy rate was 100% i.e., excellent in 7, good in 5. OFLX is one of the useful drugs in the treatment of M. pneumoniae pneumonia.
 ...
PMID:[Clinical evaluations of ofloxacin in the treatment of Mycoplasma pneumoniae pneumonia in adults]. 234 47

Epidemic respiratory tract infections occurred among elementary school children in Hiroshima prefecture during June, July and August, 1987. Forty (59%) of 68 children who were enrolled in an elementary school were confirmed to have respiratory diseases during this period, ten of whom were hospitalized with diagnoses of pneumonias. Diagnoses of M. pneumoniae infection were made from secretions obtained by throat swabs, and by serological studies of blood specimens. Twenty-four (77%) of the 31 patients examined were confirmed to have M. pneumoniae infections. Twenty-three of them had upper respiratory tract infections with cough and fever; two had pneumonia, one with myringitis. PPLO-broth, SP-4 broth and diphasic medium were used for M. pneumoniae isolation. Among these, SP-4 broth proved to have the highest isolation rate.
 ...
PMID:[Respiratory tract infections due to Mycoplasma pneumoniae in elementary school children; a case report]. 251 7

Mycoplasma pneumoniae is a pathogen of the human species which causes primarily acute respiratory diseases including pneumonia. It is transmitted from person through the respiration, and results in small epidemics. Most infected persons only develop pharyngitis or tracheobronchitis, whereas pneumonia develops in 3-30% depending on the age and characteristics of the evaluated group. Mycoplasma pneumoniae is the causative organism of 20% of community acquired pneumonias in the general population; this proportion rises to 60% in closed groups and in individuals below age 20 years. Two cases of Mycoplasma pneumoniae pneumonia identified in a single family are reported, together with a case of tracheobronchitis most likely caused by the same organism. The clinical, diagnostic, therapeutic and preventive approaches to the mycoplasma infections are discussed, and also the therapeutic approach to be recommended, in primary care, to young patients with pneumonia.
 ...
PMID:[Familial outbreak of Mycoplasma pneumoniae pneumonia]. 251 59

A new oral macrolide, clarithromycin (TE-031, A-56268), was evaluated for its safety, efficacy and pharmacokinetics in 33 children. TE-031 was effective in all cases of mycoplasmal pneumonia, pneumococcal pneumonia, streptococcal pharyngitis, pertussis and Campylobacter gastroenteritis. The pharmacokinetic availability of TE-031 granule and tablets was much better than the older macrolides; serum half-lives of TE-031 averaged 3.2 +/- 0.25 hours (for the granule preparation). No clinical adverse reaction was encountered, but cases of transient mild elevation of the serum GPT (2 cases) and eosinophilia (2 cases) were encountered. From these preliminary data, TE-031 seems to have a place in the treatment of pediatric infectious diseases.
 ...
PMID:[Clinical evaluation of clarithromycin, a new macrolide antibiotic in children]. 252 41

Clarithromycin (TE-031, A-56268) is a new 14-membered ring macrolide antibiotic developed by Taisho Pharmaceutical Co., Ltd. TE-031 has a methoxy group at position 6 in its structure. In the present study, we carried out laboratory and clinical investigations on TE-031 in the field of pediatrics. The obtained results are summarized as follows. The antibacterial activity of TE-031 was investigated against 16 clinically isolated strains of Streptococcus pyogenes, Staphylococcus aureus, Haemophilus influenzae, Bordetella pertussis and Campylobacter jejuni. TE-031 showed antibacterial activity comparable to erythromycin. The pattern of changes in TE-031 concentrations in the blood after administration was investigated. In subjects administered the granular preparation of TE-031, Cmax values were 0.64 micrograms/ml in 1 subject given a 5 mg/kg dosage, and 5.94 and 9.02 micrograms/ml in 2 subjects administered with 10 mg/kg. The tablet form of TE-031 was administered to 3 subjects at 5 mg/kg, and Cmax values were 2.09-3.92 micrograms/ml, while T 1/2 values were in a range of 2.9-3.8 hours. When drug concentrations in the urine were investigated, it was found that 6-hour recovery rates were 9.9% (dose: 5 mg/kg) and 53.4% (dose: 10 mg/kg) in the subjects administered the granular form, whereas recovery rates averaged 36.8% in the tablet-administered subjects. In the clinical trial, TE-031 was administered in 2-3 doses/day for 2-18 days. In cases given the granular form, dosages were 12-38 mg/kg/day, while tablets were administered at 12-29 mg/kg/day. The overall clinical efficacy rate was 92.8%, i.e., the drug was effective in 64 of 69 patients. TE-031 was ineffective in 1 case of otitis media, but efficacious in 10 of 10 (100%) cases of upper respiratory infection, 15 of 18 (83.3%) cases of bronchitis and pneumonia, 5 of 6 (83.3%) cases of pertussis, 13 of 13 (100%) cases of mycoplasmal pneumonia, 4 of 4 (100%) cases of Chlamydia psittaci pneumonia, 16 of 16 (100%) cases of gastroenteritis (including 15 cases of Campylobacter gastroenteritis), and 1 (100%) case of impetigo. In bacteriological studies conducted on the patients, the overall elimination rate was 93.1%, i.e., bacterial elimination was obtained in 27 of 29 cases. TE-031 showed especially good bacteriological efficacy (100%) against C. jejuni and B. pertussis, which were eliminated from all of 15 and 2 cases examined, respectively.(ABSTRACT TRUNCATED AT 400 WORDS)
 ...
PMID:[Laboratory and clinical studies on clarithromycin in pediatrics]. 252 42

A clinical evaluation of clarithromycin (TE-031, A-56268), a newly synthesized macrolide antibiotic, was made for its efficacy and safety in 30 patients with ages ranging from 8 month-old to 12 year- 2 month-old with mycoplasmal and bacterial infections. The obtained results are summarized below. 1. A pharmacokinetic study following oral administration of TE-031 at 10 mg/kg (granule) or 5.5 mg/kg (tablet) resulted in blood concentrations and urinary recovery rates higher than with other macrolides. 2. TE-031 was administered orally to 5 patients with Mycoplasma pneumonia, 21 patients with pneumonia or bronchopneumonia, 2 patients with pertussis and 2 patients with enterocolitis at daily dosages ranging 11.1-31.6 mg/kg divided into 3. Clinical evaluations of these 30 patients were as follows; excellent: 19 patients, good: 11 patients. The efficacy rate was 100%. 3. Neither clinical adverse reaction nor abnormal laboratory data was found in any of these 30 patients. 4. MICs of TE-031 against 10 strains of bacteria isolated from 10 patients with pneumonia or bronchopneumonia were as follows. MICs against 3, 2 and 2 out of 7 strains of Streptococcus pneumoniae were less than 0.025 microgram/ml, 0.05 microgram/ml and 0.10 microgram/ml, respectively. MIC against a strain of Haemophilus influenzae was 3.13 micrograms/ml. MICs of 2 strains of Branhamella catarrhalis were 0.20 microgram/ml. 5. TE-031 is considered to be a new useful and safe antibiotic in pediatric patient with an excellent bactericidal capacity.
 ...
PMID:[Clinical evaluation of clarithromycin in pediatric patients]. 252 47

We have carried out laboratory and clinical studies on clarithromycin (TE-031, A-56268). The results are summarized as follows. Serum and urinary concentrations of TE-031 were determined in 5 children with ages between 6 and 11 years given single oral doses of 5, 6.7, 10 and 15 mg/kg. Serum concentrations peaked at 1 hour after administration of 5, 6.7 and 15 mg/kg, and respective peak values were 1.98 micrograms/ml, 2.21 micrograms/ml and 5.58 micrograms/ml. Biological half-lives for the drug at 5, 6.7 and 15 mg/kg dose were 2.99 hours, 2.08 hours and 2.09 hours, respectively. Mean serum concentrations peaked at 2 hours after administration of 10 mg/kg, and peak values were 3.91 +/- 1.64 micrograms/ml. Biological half-lives were 3.00 +/- 0.58 hours. The 6-hour urinary recovery rates ranged from 22.7% to 23.8% after administration of 10 mg/kg, and the 6-hour urinary recoveries were 30.1%, 20.5% and 39.1% after administration of 5 mg/kg, 6.7 mg/kg and 15 mg/kg, respectively. Therapeutic responses were recorded as excellent or good in 35(89.7%) of the children, comprising 5 with tonsillitis, 3 with pharyngitis, 7 with bronchitis, 5 with pneumonia, 15 with Mycoplasma pneumonia, 1 with whooping cough and 3 with Campylobacter enteritis. The microbiological effectiveness of TE-031 on identified pathogens comprising 2 strains of Streptococcus pneumoniae, 5 strains of Haemophilus influenzae, 2 strains of Haemophilus parainfluenzae, 5 strains of Mycoplasma pneumoniae and Campylobacter spp. was satisfactory as evidenced by an eradication rate of 82.4%. No significant side effect due to the drug was observed in any cases. In conclusion, TE-031 was found to be efficacious and safe for the treatment of bacterial infections in children.
 ...
PMID:[Laboratory and clinical studies of clarithromycin in pediatric fields]. 252 48

Clarithromycin (TE-031, A-56268) was given orally to 25 children with acute bacterial infections including 5 with bronchitis, 8 with pneumonia, 4 with Mycoplasma pneumonia, 2 with pertussis and 6 with Campylobacter enteritis. Good to excellent clinical responses were obtained in 22 patients with bacterial eradication of all 10 strains. No side effect was observed. From the above clinical results, it appears that TE-031 is a useful antibiotic for the treatment of pediatrics with various bacterial infections.
 ...
PMID:[Clinical observations with clarithromycin in pediatrics]. 252 54


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>